ERBB2 and breast cancer: For example, trastuzumab deruxtecan (TDxD) has recently demonstrated a clinically relevant benefit in BC patients with HER2-low receptor status [94], defined as HER2 1+, 2+/ISH negative, and even as HER2-null [95].